Skip to content
Screener

Celldex Therapeutics CLDX Grant — Revenue

Other product segments

Service
$7K0.0%

Similar metrics at other companies

CRISPR Therapeutics logo
CRSPGrant — Revenue
$458K-47.1%
Kopin logo
KOPNGrant — Revenue
$3.44M+1,505%
Kopin logo
KOPNGrant Income — Revenue
$3.44M+1,504%
Organogenesis Holdings Inc. logo
ORGOGrant — Revenue
$950K+320%
Blink Charging Co. logo
BLNKGrant And Fee Rebate — Revenue
$33K+3.1%
American Public Education logo
APEIInstructional services, net of grants and scholarships — Revenue
$158.86M+5.7%

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Operating income-$80.6M-26.3%
Net income-$73.5M-29.9%
EPS (diluted)-$0.94-10.6%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Revenues:
Product development and licensing agreements$7$7$7$57
Contracts and grants15723301,367
Total revenues22730371,424
Operating expenses:
Research and development67,54254,196140,543106,810
General and administrative13,10310,39124,55221,211
Total operating expenses80,64564,587165,095128,021

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's grant — revenue?
Celldex Therapeutics (CLDX) reported grant — revenue of $15K in Q2 2026.
How has Celldex Therapeutics's grant — revenue changed year-over-year?
Celldex Therapeutics's grant — revenue decreased by 97.9% year-over-year, from $723K to $15K.
What is the long-term trend for Celldex Therapeutics's grant — revenue?
Over 4 years (2021 to 2025), Celldex Therapeutics's grant — revenue has grown at a -25.6% compound annual growth rate (CAGR), from $4.62M to $1.42M.
What does grant — revenue mean?
This metric represents the revenue recognized from government or institutional grants awarded to support specific research and development activities. It reflects the company's ability to secure non-dilutive funding to offset the costs of advancing its clinical pipeline and immunotherapy technologies. Fluctuations in this metric indicate the timing and volume of research milestones achieved under collaborative or grant-funded agreements.

Ask your AI about Celldex Therapeutics's grant — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude